Karuna Therapeutics has raised $68 million to further develop its neurology drug KarXT, which is in phase 2 clinical development for acute psychosis in patients with schizophrenia.
A panel of advisers to the FDA has voted in favour of approving Johnson & Johnson’s experimental nasal spray for depression, esketamine, bringing the medicine closer to approval.
NICE has recommended digital cognitive behavioural therapy (CBT) should be used as a first-line treatment for children and young people with mild depression.
Mental health services in the UK are falling behind physical health services because of outdated commissioning services in the National Health Service, according to a new report.
Otsuka seems to think it’s onto something by using digital tech to aid treatment of mental health disorders: in November 2017 its Abilify MyCite, a combination of the company’s antipsychoti
Otsuka is once again betting on digital as a new avenue for depression treatment by collaborating with Click Therapeutics to develop and commercialise a ‘prescriptio